The DOI matches its Crossref record; 164 of the 165 references it cites were found in a registry or an index.
Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Open accessAbstract
Bacterial infections are very common and represent one of the most important reasons of progression of liver failure, development of liver-related complications, and mortality in patients with cirrhosis. In fact, bacterial infections may be a triggering factor for the occurrence of gastrointestinal bleeding, hypervolemic hyponatremia, hepatic encephalopathy, kidney failure, and development of acute-on-chronic liver failure. Moreover, infections are a very common cause of repeated hospitalizations, impaired health-related quality of life, and increased healthcare costs in cirrhosis. Bacterial infections develop as a consequence of immune dysfunction that occurs progressively during the course of cirrhosis. In a significant proportion of patients, infections are caused by gram-negative bacteria from intestinal origin, yet gram-positive bacteria are a frequent cause of infection, particularly in hospitalized patients. In recent years, infections caused by multidrug-resistant bacteria are becoming an important clinical problem in many countries. The reduction of the negative clinical impact of infections in patients with cirrhosis may be achieved by a combination of prophylactic measures, such as administration of antibiotics, to reduce the occurrence of infections in high-risk groups together with early identification and management of infection once it has developed. Investigation on the mechanisms of altered gut microflora, translocation of bacteria, and immune dysfunction may help develop more effective and safe methods of prevention compared to those that are currently available. Moreover, research on biomarkers of early infection may be useful in early diagnosis and treatment of infections. The current manuscript reports an in-depth review and a position statement on bacterial infections in cirrhosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Norfloxacin, a poorly absorbed quinolone, is currently one of the drugs of choice for the primary or secondary prophylaxis of spontaneous bacterial peritonitis and infections in high-risk patients with cirrhosis 108.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [108]
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Bone, R. C., BALK, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · CHEST Journal · doi:10.1378/chest.101.6.1644 · Cited by 13,317
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,371
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173
Moreau, R., Jalan, R., Ginès, P., Pavesi, M., Angeli, P., Córdoba, J., Durand, F., Gustot, T., Saliba, F., Domenicali, M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.042 · Cited by 3,041
Self-citationde Franchis, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.004 · Cited by 2,291
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Flagged first, then by citations
1 of the 165 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Bone, 2009, Chest, 136, 864
- Zapater, 2007, Presence of bacterial DNA is a new survival indicator in patients with cirrhosis and non-infected ascitic fluid, Hepatology, 46, A40
Cited by
Sorted by citations
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,820
Self-citationEASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A. A., Laleman, W., & Ginès, P. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.024 · Cited by 3,033
Self-citationGinès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663
Self-citationLiver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
Albillos, A., Lario, M., & Álvarez-Mon, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.010 · Cited by 1,242
Self-citation
Metadata
- Authors
- Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., Albillos, A., Lammert, F., Wilmer, A., Mookerjee, R., Vila, J., Garcia-Martinez, R., Wendon, J., Such, J., Cordoba, J., Sanyal, A., Garcia-Tsao, G., Arroyo, V., Burroughs, A., & Ginès, P.
- Affiliations
- The Royal Free Hospital (GB)
- University Hospital of Bern (CH)
- University of California San Diego (US)
- Inserm (FR)
- University of Padua (IT)
- Medical University of Graz (AT)
- Université Libre de Bruxelles (BE)
- University of Bologna (IT)
- Universitätsklinikum des Saarlandes (DE)
- Universitair Ziekenhuis Leuven (BE)
- King's College London (GB)
- Instituto de Salud Carlos III (ES)
- Virginia Commonwealth University (US)
- Corresponding author
- Ginès, Pere
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 60
- Issue
- 6
- Pages
- 1310-1324
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2136919496
- Cited by
- 906
- References
- 165
- Citations by year
- 2026: 35 · 2025: 52 · 2024: 63 · 2023: 56 · 2022: 88 · 2021: 105 · 2020: 83 · 2019: 79 · 2018: 102 · 2017: 84 · 2016: 72 · 2015: 65 · 2014: 22
- FWCI
- 45.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
- Padua Research Archive (University of Padova) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Funders
- Fondo de Investigación Sanitaria (FIS PI08/0126, FIS PI12/00330)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- bacterial infection, liver cirrhosis, immune dysfunction, Gram-negative bacteria, Gram-positive bacteria, multidrug-resistant bacteria, infection control, antibiotic prophylaxis, gut microbiota, bacterial translocation, acute-on-chronic liver failure, infection biomarkers, early infection detection, hospitalization
- MeSH terms
- Anti-Bacterial Agents, Bacterial Infections, Gastroenterology, Humans, Liver Cirrhosis, Practice Guidelines as Topic, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review